CD69 and neoplasm: Further, on day 10 of combination treatment, the number of activated (CD8+ CD69+) T cells in the tumor were increased (Figure 5D) and T-cell functions were enhanced, with an up-regulated expression of the effector T-cell markers, IFN-γ, Granzyme B, and KLRG1 (Figures 5E–G).